{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:09:31Z","timestamp":1790237371086,"version":"4.1.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte Corp","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is limited evidence regarding the economic burden, treatment patterns, and overall survival (OS) of patients with cholangiocarcinoma (CCA) and cancer of unknown primary (CUP) who initiated the FGFR inhibitor pemigatinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>We used the Komodo Healthcare Map to identify patients with CCA who initiated pemigatinib between 4\/17\/2020 and 5\/31\/2023. Follow-up began at initiation and lasted \u2265 1\u2009month. Outcomes included health care resource utilization (HCRU), costs, treatment patterns, and OS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Two hundred twenty-one patients were included: 78 patients (35.3%) with CUP (median follow-up, 5.9\u2009months) and 143 patients (64.7%) without CUP (median follow-up, 7.3\u2009months). Pemigatinib was similarly well-tolerated in CUP vs non-CUP. Discontinuation was observed in 43.6% vs 49.0% (P\u2009=\u2009.445). Medication possession ratio \u2265 0.80 was achieved by 71.6% vs 67.2% (P\u2009=\u2009.504). CUP was associated with significantly higher prevalence of metastatic disease (100.0% vs 63.6%), per patient per month (PPPM) ambulatory HCRU (8.2 vs 5.5), and ambulatory costs ($8584 vs $5308). Medical costs averaged $13 444 vs $9881 PPPM for CUP and non-CUP, respectively (P\u2009=\u2009.066). Median OS was significantly shorter with CUP (10.2 vs 30.7\u2009months).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although pemigatinib was similarly well-tolerated regardless of CUP status, patients with CUP incurred greater ambulatory burden and had poorer OS. Patients with CUP were more likely to have evidence of metastatic disease at pemigatinib initiation, which may help explain these results. With the advent of targeted treatments for gene-altered CCA, reflexive genomic testing should be encouraged for all patients with CUP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf352","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T12:53:40Z","timestamp":1761656020000},"source":"Crossref","is-referenced-by-count":3,"title":["Economic and clinical outcomes among patients with cholangiocarcinoma receiving pemigatinib with or without history of cancer of unknown primary"],"prefix":"10.1093","volume":"30","author":[{"given":"Sumit","family":"Verma","sequence":"first","affiliation":[{"name":"Incyte Corp ., Wilmington, DE,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3029-675X","authenticated-orcid":false,"given":"Alejandro","family":"Hughes","sequence":"additional","affiliation":[{"name":"Optum, Inc ., Eden Prairie, MN,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M","family":"Engel-Nitz","sequence":"additional","affiliation":[{"name":"Optum, Inc ., Eden Prairie, MN,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Steiger","sequence":"additional","affiliation":[{"name":"Optum, Inc ., Eden Prairie, MN,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreekant","family":"Parasuraman","sequence":"additional","affiliation":[{"name":"Incyte Corp ., Wilmington, DE,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9158-0941","authenticated-orcid":false,"given":"Milind","family":"Javle","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine, University of Texas MD Anderson Cancer Center , Houston, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunyoung S","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine, University of Texas MD Anderson Cancer Center , Houston, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Saj","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine, University of Texas MD Anderson Cancer Center , Houston, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Blecker","sequence":"additional","affiliation":[{"name":"Incyte Corp ., Wilmington, DE,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,8]]},"reference":[{"key":"2025111120321091400_oyaf352-B1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.5009\/gnl15568","article-title":"Cholangiocarcinoma: current knowledge and new developments","volume":"11","author":"Blechacz","year":"2017","journal-title":"Gut Liver"},{"key":"2025111120321091400_oyaf352-B2","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/oncolo\/oyac150","article-title":"Temporal changes in cholangiocarcinoma incidence and mortality in the United States from 2001 to 2017","volume":"27","author":"Javle","year":"2022","journal-title":"Oncologist"},{"key":"2025111120321091400_oyaf352-B3","first-page":"201","article-title":"Histological classification of liver and intrahepatic bile duct cancers in SEER registries","volume":"38","author":"Altekruse","year":"2011","journal-title":"J Registry Manag"},{"key":"2025111120321091400_oyaf352-B4","doi-asserted-by":"crossref","first-page":"370","DOI":"10.6004\/jnccn.2017.7056","article-title":"Trends in incidence and factors affecting survival of patients with cholangiocarcinoma in the United States","volume":"16","author":"Mukkamalla","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"2025111120321091400_oyaf352-B5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/liv.14095","article-title":"Cholangiocarcinoma: epidemiology and risk factors","volume":"39","author":"Khan","year":"2019","journal-title":"Liver Int"},{"key":"2025111120321091400_oyaf352-B6","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025111120321091400_oyaf352-B7","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.clinre.2020.03.024","article-title":"Epidemiology of cholangiocarcinoma: United States incidence and mortality trends","volume":"44","author":"Gad","year":"2020","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"2025111120321091400_oyaf352-B8","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","article-title":"Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma","volume":"60","author":"Bridgewater","year":"2014","journal-title":"J Hepatol"},{"key":"2025111120321091400_oyaf352-B9","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3390\/diagnostics13020233","article-title":"Diagnosis of cholangiocarcinoma","volume":"13","author":"Shin","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"2025111120321091400_oyaf352-B10","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/annonc\/mds652","article-title":"A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe","volume":"24","author":"Bertuccio","year":"2013","journal-title":"Ann Oncol"},{"key":"2025111120321091400_oyaf352-B11","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41416-022-01824-4","article-title":"Intrahepatic cholangiocarcinoma hidden within cancer of unknown primary","volume":"127","author":"Conway","year":"2022","journal-title":"Br J Cancer"},{"key":"2025111120321091400_oyaf352-B12","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJMra1303917","article-title":"Cancer of unknown primary site","volume":"371","author":"Varadhachary","year":"2014","journal-title":"N Engl J Med"},{"key":"2025111120321091400_oyaf352-B13","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3389\/fonc.2019.00402","article-title":"Does cancer of unknown primary (CUP) truly exist as a distinct cancer entity?","volume":"9","author":"Bochtler","year":"2019","journal-title":"Front Oncol"},{"key":"2025111120321091400_oyaf352-B14","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s12094-022-02806-x","article-title":"SEOM-GECOD clinical guideline for unknown primary cancer (2021)","volume":"24","author":"Losa","year":"2022","journal-title":"Clin Transl Oncol"},{"key":"2025111120321091400_oyaf352-B15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1053\/j.seminoncol.2008.10.009","article-title":"Pathologic evaluation of unknown primary cancer","volume":"36","author":"Oien","year":"2009","journal-title":"Semin Oncol"},{"key":"2025111120321091400_oyaf352-B16","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3390\/cancers13030451","article-title":"Cancer of unknown primary: challenges and progress in clinical management","volume":"13","author":"Laprovitera","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025111120321091400_oyaf352-B17","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/j.ejca.2007.06.023","article-title":"Switching benchmarks in cancer of unknown primary: from autopsy to microarray","volume":"43","author":"Pentheroudakis","year":"2007","journal-title":"Eur J Cancer"},{"key":"2025111120321091400_oyaf352-B18","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","article-title":"Forty-Year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise","volume":"21","author":"Saha","year":"2016","journal-title":"Oncologist"},{"key":"2025111120321091400_oyaf352-B19","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1245\/s10434-014-4247-8","article-title":"The ability to diagnose intrahepatic cholangiocarcinoma definitively using novel branched DNA-enhanced albumin RNA In situ hybridization technology","volume":"23","author":"Ferrone","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"2025111120321091400_oyaf352-B20","doi-asserted-by":"crossref","first-page":"v133","DOI":"10.1093\/annonc\/mdv305","article-title":"Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Fizazi","year":"2015","journal-title":"Ann Oncol"},{"key":"2025111120321091400_oyaf352-B21","doi-asserted-by":"crossref","first-page":"e2400191","DOI":"10.1200\/PO.24.00191","article-title":"Personalized therapy selection by integration of molecular cancer classification by the 92-gene assay and tumor profiling in patients with cancer of unknown primary","volume":"8","author":"Fuentes Bayne","year":"2024","journal-title":"JCO Precis Oncol."},{"key":"2025111120321091400_oyaf352-B22","doi-asserted-by":"crossref","first-page":"102035","DOI":"10.1016\/j.esmoop.2023.102035","article-title":"Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study","volume":"8","author":"Westphalen","year":"2023","journal-title":"ESMO Open"},{"key":"2025111120321091400_oyaf352-B23","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1200\/GO.20.00030","article-title":"Lack of targetable FGFR2 fusions in endemic fluke-associated cholangiocarcinoma","volume":"6","author":"Kongpetch","year":"2020","journal-title":"JCO Glob Oncol"},{"key":"2025111120321091400_oyaf352-B24","doi-asserted-by":"crossref","first-page":"71","DOI":"10.32074\/1591-951X-859","article-title":"FGFR2 testing in cholangiocarcinoma: translating molecular studies into clinical practice","volume":"115","author":"Angerilli","year":"2023","journal-title":"Pathologica"},{"key":"2025111120321091400_oyaf352-B25","doi-asserted-by":"crossref","first-page":"103488","DOI":"10.1016\/j.esmoop.2024.103488","article-title":"An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202","volume":"9","author":"Vogel","year":"2024","journal-title":"ESMO Open"},{"key":"2025111120321091400_oyaf352-B26","doi-asserted-by":"crossref","first-page":"oyae204","DOI":"10.1093\/oncolo\/oyae204","article-title":"Real-world use of pemigatinib for the treatment of cholangiocarcinoma in the US","volume":"30","author":"Saverno","year":"2025","journal-title":"Oncologist"},{"key":"2025111120321091400_oyaf352-B27","doi-asserted-by":"crossref","first-page":"113587","DOI":"10.1016\/j.ejca.2024.113587","article-title":"Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: a joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies","volume":"200","author":"Parisi","year":"2024","journal-title":"Eur J Cancer"},{"key":"2025111120321091400_oyaf352-B28","volume-title":"NCI Comorbidity Index Overview","author":"National Cancer Institute","year":"2014"},{"key":"2025111120321091400_oyaf352-B29","author":"Statistics USBoL","year":"2024"},{"key":"2025111120321091400_oyaf352-B30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1524-4733.2006.00139.x","article-title":"A checklist for medication compliance and persistence studies using retrospective databases","volume":"10","author":"Peterson","year":"2007","journal-title":"Value Health"},{"key":"2025111120321091400_oyaf352-B31","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s41669-022-00371-1","article-title":"Healthcare costs before and after diagnosis of cancer of unknown primary versus ovarian cancer in Australia","volume":"7","author":"Gordon","year":"2023","journal-title":"Pharmacoecon Open"},{"key":"2025111120321091400_oyaf352-B32","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s41669-017-0051-2","article-title":"The potential clinical and economic value of primary tumour identification in metastatic cancer of unknown primary tumour: a population-based retrospective matched cohort study","volume":"2","author":"Hannouf","year":"2018","journal-title":"Pharmacoecon Open"},{"key":"2025111120321091400_oyaf352-B33","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"2025111120321091400_oyaf352-B34","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1007\/s12325-022-02342-8","article-title":"Real-World analysis of treatment patterns, healthcare utilization, costs, and mortality among people with biliary tract cancers in the USA","volume":"39","author":"Healey","year":"2022","journal-title":"Adv Ther"},{"key":"2025111120321091400_oyaf352-B35","doi-asserted-by":"crossref","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"2025111120321091400_oyaf352-B36","first-page":"550","article-title":"Biomarker testing rates among metastatic cancer patients with receipt of anti-cancer systemic therapy: a real-world data analysis","volume":"19","author":"DaCosta Byfield","year":"2023","journal-title":"Am Soc Clin Oncol"},{"key":"2025111120321091400_oyaf352-B37","doi-asserted-by":"crossref","first-page":"6633","DOI":"10.1200\/JCO.2023.41.16_suppl.6633","article-title":"Real-world analysis of commercially insured and Medicare Advantage patients with advanced cancer and rates of molecular testing","volume":"41","author":"DaCosta Byfield","year":"2023","journal-title":"Am Soc Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf352\/65004373\/oyaf352.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/11\/oyaf352\/65004373\/oyaf352.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/11\/oyaf352\/65004373\/oyaf352.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T01:32:21Z","timestamp":1762911141000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf352\/8305166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,11]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf352","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,11]]},"article-number":"oyaf352"}}